Home > In process > Frontotemporal dementia patient-derived iPSC neurons show cell pathological hallmarks and evidence for synaptic dysfunction and DNA damage. > print

001     285263
005     20260219160655.0
024 7 _ |a 10.1038/s41380-025-03272-x
|2 doi
024 7 _ |a pmid:41006764
|2 pmid
024 7 _ |a 1359-4184
|2 ISSN
024 7 _ |a 1476-5578
|2 ISSN
037 _ _ |a DZNE-2026-00205
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Huber, Nadine
|b 0
245 _ _ |a Frontotemporal dementia patient-derived iPSC neurons show cell pathological hallmarks and evidence for synaptic dysfunction and DNA damage.
260 _ _ |a [London]
|c 2026
|b Springer Nature
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1771513525_3216
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Frontotemporal dementia (FTD) is the second most common cause of dementia in patients under 65 years, characterized by diverse clinical symptoms, neuropathologies, and genetic background. Synaptic dysfunction is suggested to play a major role in FTD pathogenesis. Disturbances in the synaptic function can also be associated with the C9orf72 repeat expansion (C9-HRE), the most common genetic mutation causing FTD. C9-HRE leads to distinct pathological hallmarks, such as C9orf72 haploinsufficiency and development of toxic RNA foci and dipeptide repeat proteins (DPRs). FTD patient brains, including those carrying the C9-HRE, are also characterized by neuropathologies involving accumulation of TDP-43 and p62/SQSTM1 proteins. This study utilized induced pluripotent stem cell (iPSC)-derived cortical neurons from C9-HRE-carrying or sporadic FTD patients and healthy control individuals. We report that the iPSC neurons derived from C9-HRE carriers developed typical C9-HRE-associated hallmarks, including RNA foci and DPR accumulation. All FTD neurons demonstrated increased cytosolic accumulation of TDP-43 and p62/SQSTM1 and changes in nuclear size and morphology. In addition, the FTD neurons displayed reduced number and altered morphologies of dendritic spines and significantly altered synaptic function indicated by a decreased response to stimulation with GABA. These structural and functional synaptic disturbances were accompanied by upregulated gene expression in the FTD neurons related to synaptic function, including synaptic signaling, glutamatergic transmission, and pre- and postsynaptic membrane, as compared to control neurons. Pathways involved in DNA repair were significantly downregulated in FTD neurons. Only one gene, NUPR2, potentially involved in DNA damage response, was differentially expressed between the sporadic and C9-HRE-carrying FTD neurons. Our results show that the iPSC neurons from FTD patients recapitulate pathological changes of the FTD brain and strongly support the hypothesis of synaptic dysfunction as a crucial contributor to disease pathogenesis in FTD.
536 _ _ |a 354 - Disease Prevention and Healthy Aging (POF4-354)
|0 G:(DE-HGF)POF4-354
|c POF4-354
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a C9orf72 Protein
|2 NLM Chemicals
650 _ 7 |a DNA-Binding Proteins
|2 NLM Chemicals
650 _ 7 |a Sequestosome-1 Protein
|2 NLM Chemicals
650 _ 7 |a SQSTM1 protein, human
|2 NLM Chemicals
650 _ 7 |a C9orf72 protein, human
|2 NLM Chemicals
650 _ 7 |a TARDBP protein, human
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Induced Pluripotent Stem Cells: metabolism
|2 MeSH
650 _ 2 |a Induced Pluripotent Stem Cells: pathology
|2 MeSH
650 _ 2 |a Frontotemporal Dementia: genetics
|2 MeSH
650 _ 2 |a Frontotemporal Dementia: pathology
|2 MeSH
650 _ 2 |a Frontotemporal Dementia: metabolism
|2 MeSH
650 _ 2 |a Neurons: metabolism
|2 MeSH
650 _ 2 |a Neurons: pathology
|2 MeSH
650 _ 2 |a C9orf72 Protein: genetics
|2 MeSH
650 _ 2 |a C9orf72 Protein: metabolism
|2 MeSH
650 _ 2 |a DNA Damage: genetics
|2 MeSH
650 _ 2 |a DNA Damage: physiology
|2 MeSH
650 _ 2 |a Synapses: metabolism
|2 MeSH
650 _ 2 |a Synapses: pathology
|2 MeSH
650 _ 2 |a DNA-Binding Proteins: metabolism
|2 MeSH
650 _ 2 |a DNA-Binding Proteins: genetics
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Sequestosome-1 Protein: metabolism
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a DNA Repeat Expansion: genetics
|2 MeSH
650 _ 2 |a Brain: metabolism
|2 MeSH
700 1 _ |a Hietanen, Tomi
|b 1
700 1 _ |a Heikkinen, Sami
|0 0000-0002-6083-2402
|b 2
700 1 _ |a Shakirzyanova, Anastasia
|b 3
700 1 _ |a Hoffmann, Dorit
|b 4
700 1 _ |a Rostalski, Hannah
|0 0000-0002-4672-0850
|b 5
700 1 _ |a Dhingra, Ashutosh
|0 P:(DE-2719)2811729
|b 6
|u dzne
700 1 _ |a Rodriguez-Nieto, Salvador
|0 P:(DE-2719)2812129
|b 7
|u dzne
700 1 _ |a Kärkkäinen, Sari
|b 8
700 1 _ |a Koskuvi, Marja
|0 0000-0002-1646-9992
|b 9
700 1 _ |a Korhonen, Eila
|b 10
700 1 _ |a Hartikainen, Päivi
|b 11
700 1 _ |a Pylkäs, Katri
|b 12
700 1 _ |a Krüger, Johanna
|0 0000-0003-4346-1133
|b 13
700 1 _ |a Malm, Tarja
|0 0000-0002-9530-7472
|b 14
700 1 _ |a Takalo, Mari
|b 15
700 1 _ |a Hiltunen, Mikko
|b 16
700 1 _ |a Koistinaho, Jari
|0 0000-0001-6559-1153
|b 17
700 1 _ |a Portaankorva, Anne M
|b 18
700 1 _ |a Solje, Eino
|0 0000-0001-9940-9524
|b 19
700 1 _ |a Haapasalo, Annakaisa
|0 0000-0003-0959-2957
|b 20
773 _ _ |a 10.1038/s41380-025-03272-x
|g Vol. 31, no. 3, p. 1500 - 1516
|0 PERI:(DE-600)1502531-7
|n 3
|p 1500 - 1516
|t Molecular psychiatry
|v 31
|y 2026
|x 1359-4184
856 4 _ |u https://pub.dzne.de/record/285263/files/DZNE-2026-00205.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/285263/files/DZNE-2026-00205.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2811729
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2812129
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-354
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Prevention and Healthy Aging
|x 0
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2025-11-07
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-11-07
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-11-07
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MOL PSYCHIATR : 2022
|d 2025-11-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-11-07
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-11-07
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b MOL PSYCHIATR : 2022
|d 2025-11-07
920 1 _ |0 I:(DE-2719)1210002
|k AG Heutink
|l Genome Biology of Neurodegenerative Diseases
|x 0
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1210002
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21